PTC Therapeutics Stock Soars on Novartis Licensing Agreement
Shares of PTC Therapeutics surged Monday when the pharmaceutical firm announced it struck a nearly $2 billion license and ...
Novartis in up to $2.9 billion licensing deal for PTC Therapeutics Huntington's disease drug
Swiss drugmaker Novartis will pay up to $2.9 billion for PTC Therapeutics' promising experimental drug for a neurological ...
PTC Therapeutics signs up to $2.9 billion licensing deal with Novartis
PTC Therapeutics has signed an up to $2.9 billion licensing deal with Novartis AG for the U.S. company's experimental drug ...
GlobalData on MSN1d
Novartis and PTC Therapeutics link to develop Huntington’s therapy
Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/90.BMDkfsfZ.js ...
FierceBiotech2d
Novartis pays PTC $1B upfront for midphase Huntington's program, reestablishing itself in R&D race
Novartis is paying $1 billion upfront for global rights to PTC Therapeutics’ midphase Huntington's disease program, helping ...
PTC Therapeutics price target raised to $71 from $47 at UBS
UBS raised the firm’s price target on PTC Therapeutics (PTCT) to $71 from $47 and keeps a Buy rating on the shares. PTC Therapeutics on Monday announced a global licensing and collaboration agreement ...
Business Insider14h
PTC Therapeutics price target raised to $32 from $26 at Citi
Citi raised the firm’s price target on PTC Therapeutics (PTCT) to $32 from $26 and keeps a Sell rating on the shares. The firm updated the company’s model to reflect the Novartis collaboration, which ...
6 Analysts Assess PTC: What You Need To Know
Throughout the last three months, 6 analysts have evaluated PTC PTC, offering a diverse set of opinions from bullish to ...
PTC Therapeutics stock jumps on $2.9B license deal with Novartis for Huntington's disease drug candidate
PTC Therapeutics surges 21% after entering exclusive global collaboration with Novartis for Huntington's disease program ...
PTC (NASDAQ:PTC) Price Target Raised to $210.00
PTC (NASDAQ:PTC – Free Report) had its price objective upped by JPMorgan Chase & Co. from $200.00 to $210.00 in a report ...
BioPharma Dive2d
Novartis wagers billions of dollars on PTC Huntington’s drug
At the center of a new licensing deal is an experimental medicine, PTC518, which is currently being tested in a roughly ...
Investor's Business Daily on MSN4h
PTC Getting Closer To Key Technical Benchmark
Rating, from 69 to 73.Please watch the video at Investors.com - Find Top Growth Stocks With The IBD Screen Of The DayThis ...